Skip to content

SAS115359, A SAFETY AND EFFICACY STUDY OF INHALED FLUTICASONE PROPIONATE/SALMETEROL COMBINATION VERSUS INHALED FLUTICASONE PROPIONATE IN THE TREATMENT OF ADOLESCENT AND ADULT SUBJECTS WITH ASTHMA

SAS115359, A SAFETY AND EFFICACY STUDY OF INHALED FLUTICASONE PROPIONATE/SALMETEROL COMBINATION VERSUS INHALED FLUTICASONE PROPIONATE IN THE TREATMENT OF ADOLESCENT AND ADULT SUBJECTS WITH ASTHMA

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-063-12
Enrollment
167
Registered
2013-01-28
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

SUBJECTS WILL PARTICIPATE IN THE STUDY FOR A MAXIMUM OF 29 WEEKS, COMPRISED OF A RANDOMIZATION VISIT (VISIT 2) FOLLOWED BY A TREATMENT PERIOD OF 26 WEEKS AND A 1-WEEK FOLLOW-UP PHONE CALL TO ASSESS FO

Sponsors

GlaxoSmithKline,
Lead Sponsor

Eligibility

Age
12 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. INFORMED CONSENT: • THE SUBJECT AND/OR THE SUBJECT´S LEGAL GUARDIAN (IF APPLICABLE) MUST PROVIDE WRITTEN INFORMED ASSENT/CONSENT TO TAKE PART IN THE STUDY. • SUBJECTS AND/OR THEIR LEGAL GUARDIANS (IF APPLICABLE) UNDERSTAND THAT THEY MUST COMPLY WITH STUDY TREATMENT AND STUDY ASSESSMENTS INCLUDING RECORDING OF DAILY INFORMATION REGARDING THEIR ASTHMA STATUS AND ATTEND SCHEDULED STUDY VISITS, AND BE ACCESSIBLE BY TELEPHONE. 2. SUBJECT: 12 YEARS OF AGE AND OLDER. 3. GENDER: MALE OR FEMALE. 4. ASTHMA DIAGNOSIS: PERSISTENT ASTHMA, DEFINED BY NATIONAL AND INTERNATIONAL ASTHMA GUIDELINES [GINA, 2009; NIH, 2007; ETC.] FOR AT LEAST 1 YEAR PRIOR TO STUDY ENROLMENT. IF THE SUBJECT IS NAÏVE TO THE STUDY SITE, THE DIAGNOSIS OF ASTHMA MUST BE CONFIRMED BY SUBJECT HISTORY. NOTE: INVESTIGATORS MUST USE APPROPRIATE MEANS TO ENSURE THE SUBJECT´S ASTHMA DIAGNOSIS (E.G., SUBJECT HISTORY, PHARMACY RECORDS, OR CHART RECORDS, ETC.). 5. PEF: A CLINIC PEF ≥ 50% OF PREDICTED NORMAL VALUE. PERCENT PREDICTED PEF VALUES MUST BE CALCULATED USING NHANES III WITH RELEVANT EQUATIONS THAT ADJUST FOR RACE AND NATIONAL ORIGIN. [HANKINSON, 1999; HANKINSON, 2010].

Exclusion criteria

Exclusion criteria: 1. HISTORY OF LIFE-THREATENING ASTHMA: DEFINED FOR THIS PROTOCOL AS AN ASTHMA EPISODE THAT REQUIRED INTUBATION AND/OR WAS ASSOCIATED WITH HYPERCAPNEA REQUIRING NON-INVASIVE VENTILATORY SUPPORT. 2. CONCURRENT RESPIRATORY DISEASE: SUBJECTS WITH CURRENT EVIDENCE OF PNEUMONIA, PNEUMOTHORAX, ATELECTASIS, PULMONARY FIBROTIC DISEASE, ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS, CYSTIC FIBROSIS, BRONCHOPULMONARY DYSPLASIA, OR OTHER RESPIRATORY ABNORMALITIES OTHER THAN ASTHMA. 3. CHRONIC OBSTRUCTIVE PULMONARY DISEASE: SUBJECTS WITH CURRENT EVIDENCE OF, OR EVER BEEN TOLD BY A PHYSICIAN THAT THEY HAVE CHRONIC BRONCHITIS, EMPHYSEMA, OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE. 4. TOBACCO USE: HISTORY OF SMOKING > 10 PACK YEARS (NUMBER OF PACK YEARS (NUMBER OF CIGARETTES PER DAY/20) X NUMBER OF YEARS SMOKED). 5. EXERCISE-INDUCED ASTHMA: SUBJECTS WITH EXERCISE INDUCED ASTHMA (AS THE ONLY ASTHMA-RELATED DIAGNOSIS) NOT REQUIRING DAILY ASTHMA CONTROL MEDICINE. 6. RESPIRATORY INFECTION: CULTURE-DOCUMENTED OR SUSPECTED BACTERIAL OR VIRAL INFECTION OF THE UPPER OR LOWER RESPIRATORY TRACT, SINUS OR MIDDLE EAR THAT IS NOT RESOLVED AT RANDOMIZATION.

Countries

United States

Contacts

Public ContactYngrid Rossana Saldarriaga

PAREXEL INTERNATIONAL (PERU) S.A.

yngrid.saldarriaga@parexel.com25743090

Outcome results

None listed

Source: REPEC (via WHO ICTRP)